Partner at Lux Capital
Check size: Firm-level: Lux says it can invest from an initial $100K through high-conviction follow-ons as large as $100M across the company-building arc. This is not David's personal standard check range.
David backs scientific founders in therapeutics, R&D tooling, and biopharma infrastructure, looking for research edges early enough to matter. His research and company-building background supports a translational lens: find important science before it is broadly distributed, test whether the platform creates a repeatable advantage rather than a single asset, and build the operational infrastructure required to turn experimental insight into durable medicines or tools.
Start with the scientific insight and why it is both important and non-obvious. Bring reproducible evidence, mechanism, comparison with the current standard, translational and regulatory path, development milestones, capital requirements, and the platform or infrastructure leverage beyond a single program. Explain what remains unpublished or uniquely knowable and why this team can move before the edge diffuses.
Entrepreneurs and innovators with differentiated therapeutic science, enabling R&D tools, or infrastructure that accelerates drug development. Lux's broader lens favors technically hard, early, confusing frontiers and overlooked founders; David has specifically emphasized moving quickly when a scientific idea has a short competitive half-life.
No personal pass list is published. His stated search for unpublished scientific edges and Lux's frontier strategy imply limited fit for incremental programs without differentiated science, platforms whose advantage is easily copied after publication, and research that lacks a plausible translation path into a product, therapeutic, or enabling infrastructure.
Assess how quickly competitors can reproduce or act on a scientific insight after publication, what remains proprietary, and whether the team can translate the edge into data, intellectual property, infrastructure, or clinical progress before it diffuses.
Connect a reproducible scientific result to a product or therapeutic path, then test whether the underlying tools, data, or operating system create repeatable leverage beyond one experiment or asset.
“The half-life of a good idea in biotech has been shortened.”
— https://www.linkedin.com/posts/davidkmyang_us-vcs-race-to-tap-chinas-biotech-innovation-activity-7333944650480685057-KYfH
“We want to get into these ideas even before they get published.”
— https://www.linkedin.com/posts/davidkmyang_us-vcs-race-to-tap-chinas-biotech-innovation-activity-7333944650480685057-KYfH
+ 38 more investments. View fund →